| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/31/2006 | US20060194293 Rb1 gene induced protein (rb1cc1) and gene |
| 08/31/2006 | US20060194292 Contains insulin-like growth factor-I, insulin-like growth factor binding protein 3 and integrin-binding domain of vitronectin ; wound healing; surgical implant, prosthesis, scaffold, wound or burn dressing |
| 08/31/2006 | US20060194291 Comprising human immunoglobulin g1 fc region, which mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 08/31/2006 | US20060194290 Polypeptide variants with altered effector function |
| 08/31/2006 | US20060194286 Apo-2LI and Apo-3 polypeptides |
| 08/31/2006 | US20060193904 Encapsulation of drugs in liposomes; encapsulated transition metal ions and encapsulated drugs, where if the drug is soley doxorubicin, the metal ion is not solely manganese, and the liposomes do not comprise an ionophore |
| 08/31/2006 | US20060193903 hydrophobic drug having (a) glycoside like GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal- as sugar moiety (b) phosphatidylcholines (c) stearylamine/oleylamine; composition improves the low solubility of gylcoside; cholestenol/ ceramide/naphthalene-2-methanol -glycoside anticancer drug; improved drug delivery |
| 08/31/2006 | US20060193867 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
| 08/31/2006 | US20060193852 immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma; single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen; domains are arranged in the order VLCD19-VHCD19-VHCD3-VLCD3; vector; cell |
| 08/31/2006 | US20060193828 Expression enhancer for HM1.24 antigen |
| 08/31/2006 | US20060193826 Methods to mobilize progenitor/stem cells |
| 08/31/2006 | US20060193823 Hydrolytically degradable carbamate derivatives of poly (Ethylene Glycol) |
| 08/31/2006 | US20060193772 Drugs for treating cancer |
| 08/31/2006 | DE19952957B4 Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung Modular Transport systems for molecular substances and their production and use |
| 08/31/2006 | DE10335845B4 Pheromone als Antikrebsmittel Pheromones as anticancer agents |
| 08/31/2006 | DE102005009099A1 New camptothecin-peptide derivatives, useful for treating cancer |
| 08/31/2006 | DE102005009084A1 New anthracyclin-peptide derivatives, useful for treating cancer, especially of the prostate, are cleaved, in the tumor, by prostate-specific antigen to release active antitumor agent and are transported by serum albumen |
| 08/31/2006 | DE102005008994A1 Pharmaceutical preparation used for the diagnosis and/or therapy of e.g. diabetes mellitus comprises a fusion polypeptide, a fusion peptide and a combination preparation containing zinc and organic molecules |
| 08/31/2006 | CA2752738A1 Small molecule inhibitors of mdm2 and uses thereof |
| 08/31/2006 | CA2601687A1 Pharmaceutical combination of bcr-abl and raf inhibitors |
| 08/31/2006 | CA2599439A1 Ykl-40 monoclonal antibody |
| 08/31/2006 | CA2599301A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor |
| 08/31/2006 | CA2599210A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 08/31/2006 | CA2599150A1 Anticancer agent comprising paclitaxel and a diptheria toxin mutant, crm 197 |
| 08/31/2006 | CA2599124A1 Imidazo (1,2-a) pyridine compounds as vegf-r2 inhibitors |
| 08/31/2006 | CA2599121A1 Method for production of a preparation of a solid dmso-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies |
| 08/31/2006 | CA2599115A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | CA2598995A1 Dimeric iap inhibitors |
| 08/31/2006 | CA2598993A1 Tetrahydroindolone and tetrahydroindazolone derivatives |
| 08/31/2006 | CA2598956A1 Bicyclic heteroaromatic derivatives useful as anticancer agents |
| 08/31/2006 | CA2598439A1 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| 08/31/2006 | CA2598330A1 1-(2h)-isoquinolone derivative |
| 08/31/2006 | CA2597781A1 Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing same and use thereof |
| 08/31/2006 | CA2597667A1 Anti-cancer and anti-microbial oxazolidinones and analogues |
| 08/31/2006 | CA2596133A1 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
| 08/30/2006 | EP1696030A1 TIE ligand homologues |
| 08/30/2006 | EP1696029A1 TIE ligand homologues |
| 08/30/2006 | EP1696028A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/30/2006 | EP1696027A1 Hla-dr-binding antigen peptide derived from wt1 |
| 08/30/2006 | EP1695986A2 Anti-erb B2 antibodies |
| 08/30/2006 | EP1695985A2 Humanized antibodies and methods for forming humanized antibodies |
| 08/30/2006 | EP1695982A1 Glycosylation-deficient hepatocyte growth factor |
| 08/30/2006 | EP1695980A2 Human papillomavirus E2 transactivation domain / inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 08/30/2006 | EP1695979A2 Gapped 2' modified oligonucleotides |
| 08/30/2006 | EP1695975A1 Stable crystalline salts of 5-methyltetrahydrofolic acid |
| 08/30/2006 | EP1695970A1 Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 08/30/2006 | EP1695955A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof |
| 08/30/2006 | EP1695718A2 Biodegradable polyester and Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 08/30/2006 | EP1695714A1 Genetically engineered herpes virus for the treatment of tumours |
| 08/30/2006 | EP1695702A2 Treatment of metastatic disease |
| 08/30/2006 | EP1695698A1 Anti-angiogene compositions and methods of use |
| 08/30/2006 | EP1695697A1 Anti-angiogenic compositions and methods of use |
| 08/30/2006 | EP1694845A1 Anticarcinoma antibidies and uses thereof |
| 08/30/2006 | EP1694840A2 Combination therapy associating a tgf-beta antagonist with a chemotherapeutic agent |
| 08/30/2006 | EP1694839A2 Laminin-5 modulators and uses thereof |
| 08/30/2006 | EP1694709A1 Recombinant anti-cd64-immunotoxins |
| 08/30/2006 | EP1694707A1 Human anti-idiotypic antibody fragments that mimic her-2/neu |
| 08/30/2006 | EP1694706A2 Modified anti-cd52 antibody |
| 08/30/2006 | EP1694686A1 Kinase inhibitors |
| 08/30/2006 | EP1694683A2 Synthetic process |
| 08/30/2006 | EP1694674A2 Sulfone substituted imidazo ring ethers |
| 08/30/2006 | EP1694671A2 Quinoxalines useful as inhibitors of protein kinases |
| 08/30/2006 | EP1694652A1 Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| 08/30/2006 | EP1694650A1 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
| 08/30/2006 | EP1694350A1 Use of caspase-8 inhibitors for modulating hematopoiesis |
| 08/30/2006 | EP1694340A1 Enoxaparin for the treatment of cancer |
| 08/30/2006 | EP1694338A2 Use of superoxide dismutase mimetics and reductase glutathione in the form of anticancer drugs |
| 08/30/2006 | EP1694331A1 Methods for suppressing an immune response or a treating a proliferative disorder |
| 08/30/2006 | EP1694307A2 Methods for the treatment of cancer |
| 08/30/2006 | EP1513837B1 Thiazole derivatives as phosphodiesterase iv inhibitors |
| 08/30/2006 | EP1490056B1 N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases |
| 08/30/2006 | EP1487813B1 Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders |
| 08/30/2006 | EP1442030B1 Thiopene- amd thiazolesulfonamides as antineoplastic agents |
| 08/30/2006 | EP1439885B1 Simplified sarcodictyn derivatives as anti-tumor agents |
| 08/30/2006 | EP1383772B1 Nitrogen-based camptothecin derivatives |
| 08/30/2006 | EP1373250B1 Viologen linked acridine based molecule and process for the preparation thereof |
| 08/30/2006 | EP1334188B1 Cd19-specific redirected immune cells |
| 08/30/2006 | EP1322660B1 17alpha-fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds |
| 08/30/2006 | EP1297011B1 Diagnostic uses of the t-cell protein tzon7, and of the peptides and antibodies derived therefrom |
| 08/30/2006 | EP1210430B1 Muc-1 derived peptides |
| 08/30/2006 | EP1147124B1 Steroid sulfatase inhibitors and methods for making and using the same |
| 08/30/2006 | EP0980526B1 Inhibitors of nuclear protein/nuclear receptor interaction |
| 08/30/2006 | CN1826348A Crystalline 6-n-pyridylmethylaminoindolocarbazole compounds |
| 08/30/2006 | CN1826347A Indolopyrrolocabazole derivative and antitumor agent |
| 08/30/2006 | CN1826343A Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| 08/30/2006 | CN1826336A Cyclohexanecarboxylic acid compound |
| 08/30/2006 | CN1826324A Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| 08/30/2006 | CN1826323A 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
| 08/30/2006 | CN1826319A Aryl-heteroaromatic compounds, compositions comprising them and use |
| 08/30/2006 | CN1826310A Novel aminobenzophenone compounds |
| 08/30/2006 | CN1826308A Fluorocombretastatin and derivatives thereof |
| 08/30/2006 | CN1826124A Combinations of a cathepsin K inhibitor and a bisphophonate in the treatment of bone metastasis tumor, tumor growth and tumor-induced bone loss |
| 08/30/2006 | CN1826111A Imidazole derivatives for treatment of allergic and hyperproliferative disorders |
| 08/30/2006 | CN1826106A Chromatosis remedies |
| 08/30/2006 | CN1826059A Composition containing lactic acid bacterium producing equol |
| 08/30/2006 | CN1824789A Preparation of testis specific protein 50 monoclonal antibody and polyclonal antibody and use |
| 08/30/2006 | CN1824775A Preparation technology of recombination human blood vessel inhibitor K1-3 and its application in medicine for treating tumour |
| 08/30/2006 | CN1824678A Preparation and use of testes specificity protein 50 human source antibody |
| 08/30/2006 | CN1824665A Aryl heterocyclic imidazole naphthaimide kind compound and its application |
| 08/30/2006 | CN1824657A 3-substituted-2-aryl substituted-5-(3,4,5-tri alkoxy phenyl)-1,-3,4-oxidazole derivative, its preparation method and use |